Lanean...

TOP: Time-to-Event Bayesian Optimal Phase II Trial Design for Cancer Immunotherapy

BACKGROUND: Immunotherapies have revolutionized cancer treatment. Unlike chemotherapies, immune agents often take longer to show benefit, and the complex and unique mechanism of action of these agents renders the use of multiple endpoints more appropriate in some trials. These new features of immuno...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Natl Cancer Inst
Egile Nagusiak: Lin, Ruitao, Coleman, Robert L, Yuan, Ying
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2019
Gaiak:
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8204709/
https://ncbi.nlm.nih.gov/pubmed/30924863
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djz049
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!